Clinical trial
Phase 2, Open Label Extension for Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder Previously Treated With GLYX-13 (Extension of GLYX13-C-202, NCT01684163)
NCT02192099 is registered in ClinicalTrials.gov with Naurex, Inc, an affiliate of Allergan plc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 2, Open Label Extension for Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder Previously Treated With GLYX-13 (Extension of GLYX13-C-202, NCT01684163)
- Lead sponsor
- Naurex, Inc, an affiliate of Allergan plc
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- September 8, 2014
- Completion date
- November 8, 2018
- Enrollment
- 61 (actual)
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.